Arvinas, Inc. (NASDAQ:ARVN) Receives $14.86 Average Target Price from Analysts

Arvinas, Inc. (NASDAQ:ARVN) has been assigned an average recommendation of “Hold” from the fifteen analysts that are covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $15.1429.

A number of brokerages recently weighed in on ARVN. Citigroup lifted their target price on Arvinas from $21.00 to $24.00 and gave the company a “buy” rating in a report on Monday, May 4th. Wedbush boosted their price objective on Arvinas from $9.00 to $11.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 24th. Wall Street Zen cut Arvinas from a “hold” rating to a “sell” rating in a research note on Monday, March 2nd. Barclays boosted their price objective on Arvinas from $18.00 to $20.00 and gave the stock an “overweight” rating in a research note on Wednesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Arvinas in a research note on Friday, April 10th.

Insider Activity at Arvinas

In other Arvinas news, CEO Randy Teel sold 9,657 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $9.94, for a total transaction of $95,990.58. Following the transaction, the chief executive officer owned 287,218 shares in the company, valued at $2,854,946.92. The trade was a 3.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Andrew Saik sold 11,139 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $9.94, for a total value of $110,721.66. Following the transaction, the chief financial officer owned 193,128 shares in the company, valued at approximately $1,919,692.32. This represents a 5.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 97,687 shares of company stock valued at $1,138,643 over the last 90 days. Corporate insiders own 7.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC increased its position in shares of Arvinas by 491.4% during the second quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company’s stock worth $43,000 after acquiring an additional 4,835 shares during the last quarter. Canada Pension Plan Investment Board increased its position in shares of Arvinas by 109.4% during the second quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company’s stock worth $49,000 after acquiring an additional 3,500 shares during the last quarter. State of Wyoming purchased a new stake in shares of Arvinas during the third quarter worth about $68,000. Abel Hall LLC purchased a new stake in shares of Arvinas during the fourth quarter worth about $125,000. Finally, Corient Private Wealth LLC purchased a new stake in shares of Arvinas during the fourth quarter worth about $127,000. Institutional investors and hedge funds own 95.19% of the company’s stock.

Arvinas Stock Up 3.1%

ARVN stock opened at $9.87 on Monday. Arvinas has a 52-week low of $5.90 and a 52-week high of $14.51. The stock’s fifty day simple moving average is $11.14 and its 200-day simple moving average is $11.69. The stock has a market capitalization of $636.81 million, a price-to-earnings ratio of -2.97 and a beta of 1.79.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.90) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.95) by $0.05. Arvinas had a negative return on equity of 44.38% and a negative net margin of 247.54%.The business had revenue of $15.60 million for the quarter, compared to analysts’ expectations of $16.61 million. During the same quarter last year, the firm earned $1.14 earnings per share. The business’s revenue was down 91.7% on a year-over-year basis. As a group, analysts anticipate that Arvinas will post -3.29 earnings per share for the current fiscal year.

Key Headlines Impacting Arvinas

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: Arvinas and Pfizer struck a global licensing agreement with Rigel Pharmaceuticals for exclusive rights to VEPPANU, bringing in $85 million upfront and transition payments, plus up to $320 million in additional milestones and royalties. That deal helps validate the asset and provides non-dilutive funding. Article Title
• Positive Sentiment: BTIG Research raised its price target on Arvinas to $18 from $16 and reiterated a buy rating, signaling improved analyst confidence after the latest news flow. Article Title
• Neutral Sentiment: Arvinas reported first-quarter results showing a smaller-than-expected loss per share, though revenue missed estimates. The report also highlighted pipeline progress, including FDA approval for VEPPANU, updated clinical data for ARV-102, and initiation of dosing for ARV-027. Article Title
• Neutral Sentiment: The CEO, CFO, CAO, and another insider sold shares, but the company said the transactions were tied to tax withholding obligations from vesting equity awards, which makes them less concerning than open-market selling. Article Title

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.